D. Woytowitz

发表

Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099.

Nicholas Iannotti, Taral Patel, Thomas J. Lynch, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Zoledronic Acid Markedly Improves Bone Mineral Density for Patients with Monoclonal Gammopathy of Undetermined Significance and Bone Loss

Siu-Fun Wong, J. Berenson, O. Batuman, 2008, Clinical Cancer Research.

K-Ras mutation (mut), EGFR-related, and exploratory markers as response predictors of cetuximab in first-line advanced NSCLC: Retrospective analyses of the BMS099 trial.

C. Horak, T. Lynch, S. Khambata-Ford, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

IV iron sucrose for cancer and/or chemotherapy-induced anemia in patients treated with erythropoiesis-stimulating agents

H. Ghazal, N. Gabrail, A. Mangione, 2011 .

Recurrent Mixed Cryoglobulinemia (MCS): A Case Report and Literature Review.

S. Bastacky, J. Bernardo, D. Woytowitz, 2015, Rhode Island medical journal.

B3-03: A randomized multicenter phase III study of cetuximab (Erbitux®) in combination with Taxane/Carboplatin versus Taxane/Carboplatin alone as first-line treatment for patients with advanced/metastatic Non-small cell lung cancer (NSCLC)

T. Lynch, Martin R. Weber, W. Heim, 2007 .

Randomized phase II trial of a toll-like receptor 9 agonist oligodeoxynucleotide, PF-3512676, in combination with first-line taxane plus platinum chemotherapy for advanced-stage non-small-cell lung cancer.

C. Leichman, A. Krieg, V. Hirsh, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Chronic myelogenous leukemia in eastern Pennsylvania: an assessment of registry reporting.

Roy E. Smith, J. Buchanich, K. Mertz, 2015, Journal of registry management.

Irinotecan (I), carboplatin (C), and radiotherapy (RT) followed by maintenance bevacizumab (B) in the treatment (tx) of limited-stage small cell lung cancer (LS-SCLC): Update of a phase II trial of the Minnie Pearl Cancer Research Network.

J. Hainsworth, D. Spigel, F. Greco, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bortezomib, ascorbic acid and melphalan (BAM) therapy for patients with newly diagnosed multiple myeloma: an effective and well‐tolerated frontline regimen

A. Cartmell, J. Berenson, D. Woytowitz, 2009, European journal of haematology.

Lung cancer symptoms with cetuximab/taxane/carboplatin in first-line advanced NSCLC: Analysis of the BMS099 trial.

T. Lynch, R. Hermann, W. Heim, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bortezomib, Ascorbic Acid and Melphalan (BAM) Therapy for Patients (pts) with Newly Diagnosed Multiple Myeloma (MM): An Effective and Well-Tolerated Frontline Regimen.

A. Cartmell, J. Berenson, D. Woytowitz, 2007 .

CPG 7909, a TLR9 agonist, added to first line taxane/platinum for advanced non-small cell lung cancer, a randomized, controlled phase II study

J. Mezger, C. Manegold, D. Woytowitz, 2005 .

Bortezomib, ascorbic acid and melphalan (BAM) therapy for patients with newly diagnosed multiple myeloma: an effective and well‐tolerated frontline regimen

A. Cartmell, J. Berenson, D. Woytowitz, 2009, European journal of haematology.

Tacrolimus-Induced Refractory Immune Thrombocytopenia In Solid Organ Transplant Patients

Roy E. Smith, D. Woytowitz, R. Mehta, 2013 .